Potential of iron chelators as effective antiproliferative agents

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 10-11, 1997, Pages 1164-1180

  Richardson, D R ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cancer cells; Iron; Iron chelators; Proliferation

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; IRON; PARABACTIN; PICOLINIC ACID; PYRIDOXAL ISONICOTINOYLHYDRAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER; CELL CYCLE; CELL PROLIFERATION; DNA SYNTHESIS; DRUG INDICATION; DRUG MECHANISM; HUMAN; IRON CHELATION; IRON METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031436976     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y97-156     Document Type: Review

References (158)

1. Aisen, P. 1977. Some physiochemical aspects of iron metabolism. In Iron metabolism. Ciba Foundation Symposium 51, New Series. Elsevier, North Holland, Amsterdam, pp. 1-17.
2. Alcain, F.J., Löw, H., and Crane, F.L. 1994a. Iron at the cell surface controls DNA synthesis in CC1 39 cells. Biochem. Biophys. Res. Commun. 203: 16-21.
3. Alcain, F.J., Löw, H., and Crane, F.L. 1994b. Iron reverses impermeable chelator inhibition of DNA synthesis in CC1 39 cells. Proc. Natl. Acad. Sci. U.S.A. 91: 7903-7906.
4. Aruffo, A., Murphy, T.B., Johnson, D.K., Rose, N.J., and Schomaker, V. 1982. Structural studies of Fe(III) and Cu(II) complexes of salicylaldehyde benzoyl hydrazone, a synthetic chelating agent exhibiting diverse biological properties. Inorg. Chim. Acta, 67: L25-L27.
5. Baker, E., Vitolo, M.L., and Webb, J.M. 1985. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem. Pharmacol. 34: 3011-3017.
6. Baker, E., Lloyd, D.A., Morgan, E.H., and Yeoh, G.C.T. 1988. Iron metabolism and the effect of iron chelators in rat hepatoma cells. Birth Defects, 23(5B): 89-95.
7. Baker, E., Richardson, D.R., Gross, S., and Ponka, P. 1992. Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology, 15: 492-501.
8. Bakkeren, D.L., de Jeu-Jaspars, C.M.H., Kroos, M.J., and van Eijk, H.G. 1987. Release of iron from endosomes is an early step in the transferrin cycle. Int. J. Biochem. 19: 179-186.
9. Becton, D.L., and Bryles, P. 1988. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 48: 7189-7192.
10. Becton, D.L., and Roberts, B. 1989. Antileukemic effects of desferrioxamine on human myeloid leukemia cell lines. Cancer Res. 49: 4809-4812.
11. Becrepoot, L.V., Shima, D.T., Kuroki, M., Yeo, K.T., and Voest, E.E. 1996. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res. 56: 3747-3751.
12. Bergeron, R.J., and Ingeno, M.J. 1987. Microbial iron chelator-induced cell cycle synchronisation in L1210 cells: potential in combination chemotherapy. Cancer Res. 47: 6010-6016.
13. Bhuyan, B., and Betz, T. 1968. Studies on the mode of action of the copper(II) chelate of 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone). Cancer Res. 28: 758-763.
14. Blatt, J., and Stitely, S. 1987. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. 47: 1749-1750.
15. Blatt, J., Taylor, S.R., and Stitely, S. 1988. Mechanism of antineuroblastoma activity of deferoxamine in vitro. J. Lab. Clin. Med. 112: 433-436.
16. Blatt, J., Taylor, S.R., and Kontoghiorghes, G.J. 1989. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res. 49: 2925-2927.
17. Bomford, A., Isaac, J., Roberts, S., Edwards, A., Young, S., and Williams, R. 1986. The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukemic cells. Biochem. J. 236: 243-249.
18. Booth, B., and Sartorelli, A. 1966. Synergistic action of kethoxal bis(thiosemicarbazone) and cupric ions in Sarcoma 180. Nature (London), 210: 104-105.
19. Booth, B., and Sartorelli, A. 1967. Metabolic effects of copper in intact cells: comparative activity of cupric chloride and kethoxal bis(thiosemicarbazone). Mol. Pharmacol. 3: 290-302.
20. Booth, B., Donnelly, T., Zettner, A., and Sartorelli, A. 1971. Metabolic effects of zinc in intact cells: comparative studies of zinc chloride and the zinc chelate of kethoxal bis(thiosemicarbazone). Biochem. Pharmacol. 20: 3109-3118.
21. Bottomley, S.S., Wolfe, L.C., and Bridges, K.R. 1985. Iron metabolism in K562 erythroleukemia cells. J. Biol. Chem. 260: 6811-6815.
22. Breuer, W., Epsztejn, S., and Cabantchik, Z.I. 1995. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J. Biol. Chem. 270: 24 207-24 215.
23. Bridges, K.R., and Cudkowicz, A. 1984. Effect of iron chelators on the transferrin receptor in K562 cells. J. Biol. Chem. 259: 12 970-12 977.
24. Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E., and Bishop, J.M. 1984. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (Washington, D.C.), 224: 1121-1124.
25. 1 phase of the cell cycle. Cancer Res. 53: 3968-3975.
26. Burger, R.M., Peisach, J., and Horwitz, S.B. 1981. Activated bleomycin: a transient complex of drug, iron and oxygen that degrades DNA. J. Biol. Chem. 256: 11 636-11 644.
27. Cairo, G., Vezzoni, P., Bardella, L., Schiaffonati, L., Rappocciolo, E., Levi, S., and Arosio, P. 1986. Regulation of ferritin synthesis in malignant and non-malignant lymphoid cells. Biochem. Biophys. Res. Commun. 139: 652-657.
28. Chitamber, C.R., and Seligman, P.A. 1986. Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J. Clin. Invest. 78: 1538-1546.
29. Chresta, C.M., Masters, J.R.W., and Hickman, J.A. 1996. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 56: 1834-1841.
30. Cikrt, M., Ponka, P., Necas, E., and Neuwirt, J. 1980. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol. 45: 275-283.
31. Cooper, C.E., Lynagh, G.R., Hoyes, K.P., Hider, R.C., Cammack, R., and Porter, J.B. 1996. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 271: 20 291-20 299.
32. Crane, F.L., Sun, I.L., Clarke, M.G., Grebing, C., and Low, H. 1985. Transplasma-membrane redox systems in growth and development. Biochim. Biophys. Acta, 811: 233-264.
33. DeConti, R.C., Toftness, B.R., Agrawal, K.C., Tomchick, R., Mead, J.A.R., Bertino, J.R., Sartorelli, A.C., and Cressy, W.A. 1972. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res. 32: 1455-1462.
34. Depper, J.M., Leonard, W.J., Drogula, C., Kronke, M., Waldmann, T.A., and Greene, W.C. 1985. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc. Natl. Acad. Sci. U.S.A. 82: 4230-4234.
35. Dezza, L., Cazzola, M., Danova, M., Carlo-Stella, C., Bergamaschi, G., Brugnatelli, S., Invernizzi, R., Mazzini, G., Riccardi, A., and Ascari, E. 1989. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia, 3: 104-107.
36. Donehower, L.A., and Bradley, A. 1993. The tumor suppressor p53. Biochim. Biophys. Acta, 1155: 181-205.
37. Donfrancesco, A., Deb, G., Dominici, C., Pileggi, D., Castello, M.A., and Helson, L. 1990. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 50: 4929-4930.
38. Donfrancesco, A., Deb, G., Dominici, C., Angioni, A., Caniglia, M., De Sio, L., Fidani, P., Amici, A., and Helson, L. 1992. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol. 15: 319-322.
39. Donfrancesco, A., De Bernardi, B., Carli, M., Mancini, A., Nigro, M., De Sio, L., Casale, F., Bagnulo, S., Helson, L., and Deb, G. 1995. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer, 31A: 612-615.
40. Donfrancesco, A., Deb, G., De Sio, L., Cozza, R., and Castellano, A. 1996. Role of desferrioxamine in tumor therapy. Acta Haematol. 95: 66-69.
41. Drapier, J.C., and Hibbs, J.B., Jr. 1986. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involved the iron sulphur prosthetic group and is reversible. J. Clin. Invest. 78: 790-797.
42. Estrov, Z., Tawa, A., Wang, X.-H., Dube, I.D., Sulh, H., Cohen, A., Gelfand, E.W., and Freedman, M.H. 1987. In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood, 69: 757-761.
43. Estrov, Z., Cohen, A., Gelfand, E.W., and Freedman, M.H. 1988. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am. J. Pediatr. Hematol. Oncol. 10: 288-291.
44. Evans, A.E., D'Angio, G.J., Propert, K., Anderson, J., and Hann, H.W.L. 1987. Prognostic factors in neuroblastoma. Cancer, 59: 1853-1859.
45. 1 by picolinic acid. Biochem. Biophys. Res. Commun. 76: 413-419.
46. 1 arrest induced in NRK cells by picolinic acid. Biochem. Biophys. Res. Commun. 78: 136-143.
47. Fernandez-Pol, J.A., and Johnson, G.S. 1977. Selective toxicity induced by picolinic acid in simian virus 4-transformed cells in tissue culture. Cancer Res. 37: 4276-4279.
48. Fernandez-Pol, J.A., Bono, V.H., Jr., and Johnson, G.S. 1977. Control of growth by picolinic acid: differential response of normal and transformed cells. Proc. Natl. Acad. Sci. U.S.A. 74: 2889-2893.
49. Fielding, J. 1965. Differential ferrioxamine test for measuring chelatable body iron. J. Clin. Pathol. 18: 88-97.
50. Forsbeck, K., Nilsson, K., and Kontoghiorghes, G.J. 1987. Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes. Eur. J. Haematol. 39: 318-325.
51. Frantz, C.N., Iyer, J., Frick, K.K., Eskenazi, A.E., and Derg, P.E. 1993. Iron and N-myc expression in neuroblastoma. Neuroblastoma Research Meeting, Philadelphia.
52. Frantz, C.N., Eskenazi, A.E., and Overman, D. 1995. Iron chelation cancer therapy for neuroblastoma. Proceedings of the International Conference on Bioiron. April 16-21, 1995, Asheville, N.C. p. 195.
53. French, F.A., and Blanz, E.J., Jr. 1965. The carcinostatic activity of alpha-(N) heterocyclic carboxaldehyde thiosemicarbazones. I. Isoquinoline-1-carboxaldehyde thiosemicarbazone. Cancer Res. 25: 1454-1458.
54. Fukuchi, K., Tomoyasu, S., Watanabe, H., Kaetsu, S., Tsuruoka, N., and Gomi, K. 1995. Iron deprivation results in an increase in p53 expression. Biol. Chem. Hoppe-Seyler, 376: 627-630.
55. Furst, A. 1963. Chemistry of chelation in cancer. Thomas, Springfield, Ill.
56. Goto, Y., Paterson, M., and Listowsky, I. 1983. Iron uptake and regulation of ferritin synthesis by hepatoma cells in hormone-supplemented serum-free medium. J. Biol. Chem. 258: 5248-5255.
57. Graziano, J.H., Grady, R.W., and Cerami, A. 1974. The identification of 2,3-dihydroxybenzoic acid as a potentially useful iron chelating drug. J. Pharmacol. Exp. Ther. 190: 570-575.
58. Gunshin, H., Mackenzie, B., Berger, U.V., Gunshin, Y., Romero, M.F., Boron, W.F., Nussberger, S., Gollan, J.L., and Hediger, M.A. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature (London), 388: 482-488.
59. Hainaut, P., and Milner, J. 1993. A structural role for metal ions in "wild type" conformation of the tumor suppressor protein p53. Cancer Res. 53: 1739-1742.
60. Hainaut, P., Butcher, S., and Milner, J. 1995. Temperature sensitivity for conformation is an intrinsic property of wild-type p53. Br. J. Cancer, 71: 227-231.
61. Hann, H.-W.L., Howard, M.L., and Evans, A.E. 1980. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res. 40: 1411-1413.
62. Hann, H.-W.L., Stahlhut, M.W., and Evans, A.E. 1986. Source of increased ferritin in neuroblastoma: studies with concanavalin A - Sepharose binding. J. Natl. Cancer Inst. 76: 1031-1033.
63. Hann, H.L., Stahlhut, M.W., and Hann, C.L. 1990. Effects of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology, 11: 566-569.
64. Hann, H.-W.L., Stahlhut, M.W., Rubin, R., and Maddrey, W.C. 1992. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer, 70: 2051-2056.
65. Harrison, P.M., and Arosio, P. 1996. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta, 1275: 161-203.
66. Hay, J., Shahzeidi, S., and Laurent, G. 1991. Mechanisms of bleomycin-induced lung damage. Arch. Toxicol. 65: 81-94.
67. Hentze, M.W., and Kühn, L.C. 1996. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 93: 8175-8182.
68. Hershko, C., Avramovici-Grisaru, S., Link, G., Gelfand, L., and Sarel, S. 1981. Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med. 98: 99-108.
69. Hibbs, J.B., Jr., Taintor, R.R., and Vavrin, Z. 1984. Iron depletion. Possible cause of tumor cell cytotoxicity induced by activated macrophages. Biochem. Biophys. Res. Commun. 123: 716-723.
70. Hibbs, J.B., Jr., Taintor, R.R., Vavrin, Z., and Rachlin, E.M. 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157: 87-94.
71. Hileti, D., Panayiotidis, P., and Hoffbrand, A.V. 1995. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol. 89: 181-187.
72. Hoy, T., Humphreys, J., Jacobs, A., Williams, A., and Ponka, P. 1979. Effective iron chelation following oral adminstration of an isoniazid pyridoxal hydrazone. Br. J. Haematol. 43: 443-449.
73. Hoyes, K.P., and Porter, J.B. 1993. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br. J. Haematol. 85: 393-400.
74. Hoyes, K.P., Hider, R.C., and Porter, J.B. 1992. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemic cell lines. Cancer Res. 52: 4591-4599.
75. 59Fe. Biochim. Biophys. Acta, 757: 306-315.
76. Huebers, H., Csiba, E., Josephson, B., Huebers, E., and Finch, C.A. 1982. Interaction of human diferric transferrin with reticulocytes. Proc. Natl. Acad. Sci. U.S.A. 78: 621-625.
77. Iacopetta, B.J., and Morgan, E.H. 1983. The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. J. Biol. Chem. 258: 9108-9115.
78. Iancu, T.C., Shiloh, H., and Kedar, A. 1988. Neuroblastomas contain iron-rich ferritin. Cancer, 61: 2497-2502.
79. Jacobs, A. 1977. Low molecular weight intracellular iron transport compounds. Blood, 50: 433-439.
80. Johnson, D.K., Murphy, T.B., Rose, N.J., Goodwin, W.H., and Pickart, L. 1982. Cytotoxic chelators and chelates. I. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg. Chim. Acta, 67: 159-165.
81. Keberle, H. 1964. The biochemistry of deferoxamine and its relation to iron metabolism. Ann. N.Y. Acad. Sci. U.S.A. 119: 758-768.
82. Kemp, J.D., Smith, K.M., Kanner, L.J., Gomez, F., Thorson, J.A., and Naumann, P.W. 1990. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. Blood, 76: 991-995.
83. Kemp, J.D., Thorson, J.A., Stewart, B.C., and Naumann, P.W. 1992. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity. Cancer Res. 52: 4144-4148.
84. Kew, M.C., Torrance, J.D., Derman, D., Simon, M., Macnab, G.M., Charlton, R.W., and Bothwell, T.H. 1978. Serum and tumour ferritins in primary liver cancer. Gut, 19: 294-299.
85. Keyes, S.M., and Tyrrell, R.M. 1990. Induction of the heme oxygenase gene in human skin fibroblasts by hydrogen peroxide and UVA (365 nm) radiation: evidence for the involvement of the hydroxyl radical. Carcinogenesis, 11: 787-791.
86. Kim, B.K., Huebers, H.A., and Finch, C.A. 1987. Effectiveness of oral iron chelators assayed in the rat. Am. J. Hematol. 24: 277-284.
87. Klausner, R.D., Ashwell, G., van Renswoude, J., Harford, J.B., and Bridges, K.R. 1983. Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc. Natl. Acad. Sci. U.S.A. 80: 2263-2266.
88. Kontoghiorghes, G.J. 1982. The design of orally active iron chelators for the treatment of thalassemia. Ph.D. thesis, University of Essex, Colchester, U.K. British Library Microfilm No. D66194/86.
89. Kontoghiorghes, G.J. 1986. Iron mobilisation from ferritin using α-oxohydroxy heteroaromatic chelators. Biochem. J. 233: 299-302.
90. Kontoghiorghes, G.J., and Evans, R.W. 1985. Site specificity of iron removal from transferrin by α-ketohydroxypyridone chelators. FEBS Lett. 189: 141-144.
91. Kontoghiorghes, G.J., Piga, A., and Hoffbrand, A.V. 1986a. Cytotoxic and DNA-inhibitory effects of iron chelators on human leukemic cell lines. Hematol. Oncol. 4: 195-204.
92. Kontoghiorghes, G.J., Piga, A., and Hoffbrand, A.V. 1986b. Cytotoxic effects of the lipophilic iron chelator, omadine. FEBS Lett. 204: 208-212.
93. Krakoff, I.H., Etcubanas, E., Tan, C., Mayer, K., Bethune, V., and Burchenai, J.H. 1974. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP: NSC-107392), with special reference to its Fe chelating properties. Cancer Chemother. Rep. 53: 207-212.
94. Kronke, M., Leonard, W.J., Depper, J.M., and Greene, W.C. 1985. Sequential expression of genes involved in human T lymphocyte growth and differentiation. J. Exp. Med. 161: 1593-1598.
95. Kühn, L.C., Schulman, H.M., and Ponka, P. 1990. Iron-transferrin requirements and transferrin receptor expression in proliferating cells. In Iron transport and storage. Edited by P. Ponka, H.M. Schulman, and R.C. Woodworth. CRC Press, Boca Raton, Fla. pp. 141-191.
96. Laub, R., Schneider, Y.-J., Octave, J.-N., Trouet, A., and Crichton, R.R. 1985. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilisation. Biochem. Pharmacol. 34: 1175-1183.
97. Lederman, H.M., Cohen, A., Lee, J.W.W., Freedman, M.H., and Gelfand, E. W. 1984. Deferoxamine: a reversible S phase inhibitor of human lymphocyte proliferation. Blood, 64: 748-753.
98. Leuthauser, S.W.C., Oberley, L.W., and Oberley, T.D. 1982. Antitumor activity of picolinic acid in CBA/J mice. J. Natl. Cancer Inst. 68: 123-126.
99. Levinson, W.E. 1980. Chelating substances. Antibiot. Chemother. 27: 288-306.
100. Marcus, D.M., and Zinberg, N. 1975. Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J. Natl. Cancer Inst. 55: 791-795.
101. Martell, A.E., and Smith, R.M. 1977. Critical stability constants. Vol. 3. Plenum Press, New York.
102. Modell, B., and Berdoukas, V. 1984. The clinical approach to thalassemia. Grune & Stratton, New York.
103. Modjtahedi, N., Frebourg, T., Fossar, N., Lavialle, C., Cremisi, C., and Brison, O. 1992. Increased expression of cytokeratin and ferritin-H genes in tumorigenic clones of the SW613-S human colon carcinoma cell line. Exp. Cell. Res. 201: 74-82.
104. Mostert, L.J., van Dorst, J.A.L.M., Koster, J.F., van Eijk, H.G., and Kontoghiorghes, G.J. 1987. Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte. Free Radical Res. Commun. 3: 379-388.
105. Müllner, E.W., and Kühn, L.C. 1988. A stem-loop in the 3′ untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm. Cell, 53: 815-825.
106. Munro, H.N., and Linder, M.C. 1978. Ferritin: structure, biosynthesis and role in iron metabolism. Physiol. Rev. 58: 317-396.
107. Murray, M.T., White, K., and Munro, H.N. 1987. Conservation of ferritin heavy subunit gene structure: implications for the regulation of ferritin gene expression. Proc. Natl. Acad. Sci. U.S.A. 84: 7438-7442.
108. Myers, C., Gianni, L., Zweier, J., Muindi, J., Sinha, B.K., and Eliot, H. 1986. Role of iron in adriamycin biochemistry. Fed. Proc. 45: 2792-2797.
109. Nyholm, S., Mann, G.J., Johansson, A.G., Bergeron, R.J., Gräslund, A., and Thelander, L. 1993. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. 268: 26 200-26 205.
110. Pollack, S., Aisen, P., Laskey, F.D., and Vanderhoff, G. 1976. Chelate mediated transfer of iron from transferrin to desferrioxamine. Br. J. Haematol. 34: 231-235.
111. Ponka, P., Borova, J., Neuwirt, J., and Fuchs, O. 1979a. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 97: 317-321.
112. Ponka, P., Borova, J., Neuwirt, J., Fuchs, O., and Necas, E. 1979b. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta, 586: 278-297.
113. Ponka, P., Richardson, D., Baker, E., Schulman, H.M., and Edward, J.T. 1988. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim. Biophys. Acta, 967: 122-129.
114. Ponka, P., Beaumont, C., and Richardson, D.R. 1998. Function and regulation of transferrin and ferritin. Semin. Hematol. 35: 1-21.
115. Porter, J.B., Gyparaki, M., Burke, L.C., Huehns, E.R., Sarpong, P., Saez, V., and Hider, R.C. 1988. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood, 72: 1497-1503.
116. Richardson, D.R. 1997. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim. Biophys. Acta, 1320: 45-67.
117. Richardson, D.R., and Baker, E. 1990. The uptake of iron and transferrin by the human melanoma cell. Biochim. Biophys. Acta, 1053: 1-12.
118. Richardson, D.R., and Baker, E. 1991. The release of iron and transferrin from the human melanoma cell. Biochim. Biophys. Acta, 1091: 294-302.
119. Richardson, D.R., and Baker, E. 1992. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem. 267: 13 972-13 979.
120. Richardson, D.R., and Baker, E. 1994. Two saturable mechanisms of iron uptake from transferrin human melanoma cells: the effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. J. Cell. Physiol. 161: 160-168.
121. Richardson, D.R., and Milnes, K. 1997. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89: 3025-3038.
122. Richardson, D.R., and Ponka, P. 1994. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med. 124: 660-671.
123. Richardson, D.R., and Ponka, P. 1997. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta, 1331: 1-40.
124. Richardson, D., Baker, E., Ponka, P., Wilairat, P., Vitolo, M.L., and Webb, J. 1988. Effects of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture. Birth Defects, 23(5B): 81-88.
125. Richardson, D., Ponka, P., and Baker, E. 1994. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 54: 685-689.
126. Richardson, D.R., Neumannova, V., and Ponka, P. 1995a. Nitrogen monoxide decreases iron uptake from transferrin but does not mobilize iron from prelabelled neoplastic cells. Biochim. Biophys. Acta, 1266: 250-260.
127. Richardson, D.R., Tran, E., and Ponka, P. 1995b. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86: 4295-4306.
128. Richardson, D.R., Ponka, P., and Vyoral, D. 1996. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates of iron metabolism. Blood, 87: 3477-3488.
129. Sah, P. 1954. Nicotinoyl and isonicotinoyl hydrazones of pyridoxal. J. Am. Chem. Soc. 76: 300.
130. Sappey, C., Boelaert, J.R., Legrand-Poels, S., Forceille, C., Favier, A., and Piette, J. 1995. Iron chelation decreases NF-κB and HIV type 1 activation due to oxidative stress. AIDS Res. Hum. Retroviruses, 11: 1049-1061.
131. Sartorelli, A.C., Agrawal, K.C., and Moore, E.C. 1971. Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 20: 3119-3123.
132. Seligman, P.A., Schleicher, R.B., Siriwardana, G., Domenico, J., and Gelfand, E.W. 1993. Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation. Blood, 82: 1608-1617.
133. Skala, J.P., Rogers, P.C.J., Chan, K.-W, Chao, H.Y., and Rodriguez, W.C. 1992. Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma. Prog. Clin. Biol. Res. 377: 71-78.
134. St.Pierre, T., Richardson, D.R., Baker, E., and Webb, J. 1992. A low-spin iron complex in human melanoma and rat hepatoma cells and a high spin iron(II) complex in rat hepatoma cells. Biochim. Biophys. Acta, 1135: 154-158.
135. Summers, M.R., Jacobs, A., Tudway, D., Perera, P., and Ricketts, C. 1979. Studies of desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Hematol. 42: 547-555.
136. Sun, I.L., Crane, F.L., Löw, H., and Grebing, C. 1984. Transplasma membrane redox stimulated HeLa cell growth. Biochem. Biophys. Res. Commun. 125: 649-654.
137. Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., and Greaves, M. 1981. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. U.S.A. 78: 4515-4519.
138. Taetle, R., Rhyner, K., Castagnola, D., and Mendelsohn, J. 1985. Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. J. Clin. Invest. 75: 1061-1067.
139. Taetle, R., Honeysett, J.M., and Bergeron, R. 1989. Combination iron depletion therapy. J. Natl. Cancer Inst. 81: 1229-1235.
140. Terada, N., Lucas, J.J., and Gelfand, E.W. 1991. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J. Immunol. 147: 698-704.
141. Thelander, L., and Gräslund, A. 1983. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. J. Biol. Chem. 258: 4063-4066.
142. Thelander, L., and Reichard, P. 1979. The reduction of ribonucleotides. Annu. Rev. Biochem. 48: 133-158.
143. Thelander, L., Gräslund, A., and Thelander, M. 1983. Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110: 859-865.
144. Thorstensen, K., and Aisen, P. 1990. Release of iron from diferric transferrin in the presence of rat liver membranes: no evidence of a diferric transferrin reductase. Biochim. Biophys. Acta, 1052: 29-35.
145. Tomoyasu, S., Fukuchi, K., Yajima, K., Watanabe, K., Suzuki, H., Kawakami, K., Gomi, K., and Tsuruoka, N. 1993. Suppression of HL-60 cell proliferation by deferoxamine: changes in c-myc expression. Anticancer Res. 13: 407-410.
146. Trinder, D., Zak, O., and Aisen, P. 1996. Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology, 23: 1512-1520.
147. Trowbridge, I.S., and Lopez, F. 1982. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. U.S.A. 79: 1175-1179.
148. Trowbridge, I.S., and Omary, M.B. 1981. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. U.S.A. 78: 3039-3043.
149. Tsuji, Y., Kwak, E., Saika, T., Torti, S.V., and Torti, F.M. 1993. Preferential repression of the H-subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J. Biol. Chem. 268: 7270-7275.
150. Tsuji, Y., Akebi, N., Lam, T.K., Nakabeppu, Y., Torti, S.V., and Torti, F.M. 1995. FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol. Cell. Biol. 15: 5152-5164.
151. Tyrrell, R.M. 1997. Approaches to define pathways of redox regulation of a eukaryotic gene: the heme oxygenase 1 example. Methods, 11: 313-318.
152. Ul-Haq, R., Wereley, J.P., and Chitambar, C.R. 1995. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp. Hematol. 23: 428-432.
153. Vaughn, C.B., Weinstein, R., Bond, B., Rice, R., Vaughn, R.W., McKendrick, A., Ayad, G., Rockwell, M.A., and Rocchio, R. 1987. Ferritin content in human cancerous and non-cancerous colonie tissue. Cancer Invest. 5: 7-10.
154. Vitolo, M.L., Webb, J., and Saltman, P. 1984. Release of iron from ferritin by pyridoxal isonicotinoyl hydrazone and related compounds. J. Inorg. Biochem. 20: 255-262.
155. Weinberg, E.D. 1984. Iron withholding a defense against infection and neoplasia. Physiol. Rev. 64: 65-102.
156. White, G.P., Bailey-Wood, R., and Jacobs, A. 1976. The effect of chelating agents on cellular iron metabolism. Clin. Sci. Mol. Med. 50: 145-150.
157. Williams, G.M. 1980. The pathogenesis of rat liver cancer caused by chemical carcinogens. Biochim. Biophys. Acta, 605: 167-189.
158. Wright, J.A., Chan, A.K., Choy, B.K., Hurta, R.A., McClarty, G.A., and Tagger, A.Y. 1990. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem. Cell. Biol. 68: 1364-1371.